REFERENCES
- ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62, [CSA]
- Thuerlimann B., BIG 1-98 Collaborative Group. Letrozole versus tamoxifen as adjuvant andocrine therapy for postmenopausal women with receptor positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. The Breast 2005; 14(Suppl. 1)S3, Abst. S4[CSA]
- Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anstrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 3665: 455–462, [CROSSREF], [CSA]
- Coombes R. C., Hall E., Gibson L. J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004; 350: 1081–1091, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pritchard K. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyong tamoxifen. J. Clin. Oncol. 2005; 23: 1–3, [CROSSREF], [CSA]
- Goss P. E., Ingle J. N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003; 349: 1793–1802, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lonning P. E., Geisler J., Krag L. E., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J. Clin. Oncol. 2005; 23: 1–12, [CSA]
- Hillner B., Ingle J., Chlebowski R. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 2003; 21: 4042–4057, [INFOTRIEVE], [CROSSREF], [CSA]
- Brufsky A. M., Proc. ASCO 2005
- Jakesz R., Hausmaninger H., Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—the Austrian Breast ande Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 2002; 20: 4621–4627, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gnant M., SABCS 2004
- Jordan V. C., Fritz N. F., Tormey D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987; 47: 624, [INFOTRIEVE], [CSA]
- Shapiro C. L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 2001; 19: 3306, [PUBMED], [INFOTRIEVE], [CSA]
- Perez E., SABCS 2004
- Chang J. T., Green L., Beitz J. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 2003; 349: 1676–1679, [INFOTRIEVE], [CROSSREF], [CSA]
- Durie B. G.M., Katz M., Crowley J., et al. N. Engl. J. Med. 2005; 353: 99–102, [INFOTRIEVE], [CROSSREF], [CSA]
- Lanza F. L. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat. Endocrinol. 2002; 1: 37–43, [INFOTRIEVE], [CROSSREF], [CSA]